Clinical trials: Esophagitis
Gastroesophageal Reflux Disease, Erosive Esophagitis
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
- Conditions
- Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
- Trial name
- NCT02096458
- Testing
- Dexlansoprazole
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Takeda
Erosive Esophagitis(EE), Gastroesophageal Reflux Disease (GERD)
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel…
- Trial name
- TAK-438_107 (NCT02141711)
- Testing
- TAK-438
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects
This study is a single-site, single-dose, non-randomized, open-label study to assess the absorption, metabolism, and excretion profile of [14C]X842 in healthy adult male subjects.
- Trial name
- NCT07107672
- Testing
- [14C]X842
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Eosinophilic Esophagitis
Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral…
- Trial name
- NCT07093008
- Testing
- AQ280 Capsule, AQ280 Tablet for Oral Suspension
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Reflux Oesophagitis
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men
The objectives of the study were: To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers. To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.
- Trial name
- NCT01538784
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Reflux Oesophagitis
Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers
The objective of the study was to assess whether the tolerance to the effect of YF476 on gastric pH observed with repeated doses in a previous study in healthy volunteers can be avoided by using smaller doses of YF476.
- Trial name
- NCT01597674
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Erosive Esophagitis
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008
This will be a Phase I, randomized, double-blind, positive- and placebo-controlled study to evaluate the safety, tolerability, and PK/PD of multiple oral doses of H008 in healthy adult subjects.
- Trial name
- NCT05050188
- Testing
- H008, Lansoprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu Carephar Pharmaceutical Co., Ltd.
Erosive Esophagitis, Heartburn
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily or vonoprazan 20 mg administered twice daily for 4…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06391177
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Healthy
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
The purpose of this study is to assess the potential effect and safety of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole, once daily (QD), on the steady-state pharmacokinetics and…
- Trial name
- NCT00942175
- Testing
- Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Takeda
Eosinophilic Esophagitis
A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis
An open-label phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
- Trial name
- NCT05757856
- Testing
- NDX-3315, NDX-3324, SPECT/CT Imaging
- Where
- 3 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NexEos Diagnostics, Inc.
Healthy Volunteers
A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and…
- Trial name
- NCT06831344
- Testing
- Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Erosive Gastritis, Erosive Esophagitis(EE)
Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) Tablets
Randomized, Single Dose, Two-Way Crossover, Open Label bioequivalence study to compare Vonoprazan 20 mg Film Coated Tablets versus Voquezna® 20 mg (Vonoprazan) Tablets an oral administration to healthy adults under fasting…
- Conditions
- Erosive Gastritis, Erosive Esophagitis(EE), HELICOBACTER PYLORI INFECTIONS
- Trial name
- NCT07278349
- Testing
- Vonoprazan Tablets, VOQUEZNA® Tablets
- Where
- Jordan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Reflux Oesophagitis
Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States
The objectives of the study were: To compare a single dose of YF476 at 3 dose levels, placebo and ranitidine with respect to their effects on basal- and food- stimulated gastric pH in healthy volunteers.
- Trial name
- NCT01538797
- Testing
- YF476, Ranitidine
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Eosinophilic Esophagitis (EoE)
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT05485779
- Testing
- AQ280
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Reflux Oesophagitis
Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers
The objectives of this study were: To compare repeated doses of YF476 at 2 dose levels, placebo and omeprazole with respect to their effect on basal- and food- stimulated gastric pH in healthy volunteers.
- Trial name
- NCT01599858
- Testing
- YF476, Omeprazole
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study
The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.
- Trial name
- NCT03105375
- Testing
- Single ascending dose of X842, Multiple ascending dose of X842, Losec
- Where
- Sweden
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Erosive Esophagitis
A Study to Compare the Pharmacokinetic Characteristics of CJ-12420
To compare the pharmacokinetics after administration of different formulation of CJ-12420
- Trial name
- NCT02995239
- Testing
- CJ-12420 formulation 2, CJ-12420 formulation 1
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Esophagitis, Gastroesophageal Reflux
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inhibitors (PPls). Some PPIs are already commercially available.
- Conditions
- Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
- Trial name
- NCT00284908
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- STEBA France
Eosinophilic Esophagitis, Celiac Disease
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
This is a single and multiple ascending study to characterize the safety, PK, PD and clinical effect in healthy volunteers and participants with Celiac Disease and Eosinophilic Esophagitis.
- Trial name
- NCT04593251
- Testing
- CALY-002
- Where
- 13 sites in Belgium, Finland and 3 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Calypso Biotech BV
Gastric Ulcer, Duodenal Ulcer
BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects
The purpose of this study is; To investigate whether a D961H sachet 20 mg is bioequivalent to a D961H HPMC capsule 20 mg by the assessment of percentage of time with intragastric pH>4.
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Esophagitis
- Trial name
- NCT01964131
- Testing
- D961H sachet 20 mg, D961H HPMC capsule 20 mg
- Where
- 2 sites in Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca